Additionally, the ligand for TLR9 (CpG) is being investigated in animal models and some human studies as an adjuvant for immunotherapy of allergic diseases including allergic rhinitis and asthma[3,41-43]. This evidence concerns the gene TLR9 and allergic rhinitis.